NAD+ vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
NAD+Anti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- Varies by route; IV provides direct cellular delivery
- ~2–5 hours
- Admin Route
- IV, SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 500–1000 mg
- 5–10 mg
- Frequency
- Daily for 4–10 days (loading), then monthly maintenance
- Daily to several times per week
- Key Benefits
- Restored cellular energy production (ATP)
- Sirtuin activation for longevity and metabolic regulation
- Enhanced DNA repair capacity
- Improved mitochondrial function and biogenesis
- Cognitive clarity and mental energy
- Reduced inflammation
- Addiction withdrawal support (opioids, alcohol, benzodiazepines)
- Improved sleep quality
- Enhanced athletic endurance
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Flushing and warmth during IV infusion
- Nausea during rapid IV administration
- Chest tightness (from rapid infusion — slow the rate)
- Injection site irritation (subcutaneous)
- +1 more
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —